1. Articles in category: Human Interest

    1-24 of 211 1 2 3 4 5 6 7 8 9 »
    1. Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies

      Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies

      A major obstacle to the success rate of chimeric antigen receptor (CAR-) T-cell therapy against solid tumors is the microenvironment antagonistic to T cells that solid tumors create. Conventional checkpoint blockade can silence lymphocyte antisurvival pathways activated by tumors, but because they are systemic, these treatments disrupt immune homeostasis and induce autoimmune side effects. Thus, new technologies are required to remodel the tumor milieu without causing systemic toxicities.

      Read Full Article
    2. Pediatric Cancer Immunotherapy: Opportunities and Challenges.

      Pediatric Cancer Immunotherapy: Opportunities and Challenges.

      Paediatr Drugs. 2018 Jun 12;:

      Authors: Wedekind MF, Denton NL, Chen CY, Cripe TP

      Abstract Cancer immunotherapies, widely heralded as transformational for many adult cancer patients, are becoming viable options for selected subsets of pediatric cancer patients.

      Read Full Article
      Mentions: Immunotherapy
    3. Radioiodine (131I) therapies performed in a paediatric hospital: facilities and procedures.

      Radioiodine (131I) therapies performed in a paediatric hospital: facilities and procedures.

      Australas Phys Eng Sci Med. 2018 Jun 25;:

      Authors: Bibbo G, Benger T, Sigalas V, Kirkwood I

      Abstract Radioiodine (131I) therapies on younger children with thyroid cancer and neuroblastoma can be challenging as they are required to be isolated for a period of time due to radiation safety concerns. At our hospital these therapies are performed in a purpose-built child-friendly therapy room.

      Read Full Article
    4. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.

      Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.

      Clin Nucl Med. 2018 Jun 19;:

      Authors: Willegaignon J, Crema KP, Oliveira NC, Pelissoni RA, Coura-Filho GB, Sapienza MT, Buchpiguel CA

      Read Full Article
    5. Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN

      Network Modeling of microRNA-mRNA Interactions in Neuroblastoma Tumorigenesis Identifies miR-204 as a Direct Inhibitor of MYCN

      Neuroblastoma is a pediatric cancer of the sympathetic nervous system where MYCN amplification is a key indicator of poor prognosis. However, mechanisms by which MYCN promotes neuroblastoma tumorigenesis are not fully understood. In this study, we analyzed global miRNA and mRNA expression profiles of tissues at different stages of tumorigenesis from TH-MYCN transgenic mice, a model of MYCN-driven neuroblastoma.

      Read Full Article
      Mentions: Imaging MYCN Genetics
    6. CureWorks Collaborative Launches to Accelerate Development of Immunotherapy Treatments for Childhood Cancers, Increase Access to Clinical Trials

      Seattle Children's, with participating members Children's National Health System, BC Children's Hospital and Children's Hospital Los Angeles, has launched CureWorks, an international collaborative of leading academic children's hospitals determined to accelerate the development of immunotherapy treatments for childhood cancer. CureWorks focuses on expanding immunotherapy trials and patient access around the world, as well as sharing data and collective expertise to advance novel cell therapies.

      Read Full Article
      Mentions: Immunotherapy
    7. President Signs STAR Act for Kids' Cancers.

      President Signs STAR Act for Kids' Cancers.

      Cancer Discov. 2018 Jun 07;:

      Authors:

      Abstract On June 5, President Donald Trump signed the Childhood Cancer Survivorship, Treatment, Access and Research Act, which aims to support pediatric cancer research by expanding the collection of patient biospecimens and records, improving surveillance, and investigating pediatric survivorship.

      PMID: 29880581 [PubMed - as supplied by publisher]

      Read Full Article
      Mentions: Treatment
    8. Rigorous study finds widely used treatment for infection fails young cancer patients

      A treatment designed to reduce bloodstream infections due to central venous catheters that had worked well in lab studies and is commonly used around the world, but had not been rigorously tested, failed to protect young cancer patients from recurring or...

      Read Full Article
      Mentions: Treatment
    9. Rigorous study finds widely used treatment for infection fails young cancer patients

      Rigorous study finds widely used treatment for infection fails young cancer patients

      ( St. Jude Children's Research Hospital ) St. Jude Children's Research Hospital found ethanol-lock therapy failed to prevent new or recurring infections in cancer patients with central venous catheters and was associated with increased complications.

      Read Full Article
      Mentions: Treatment
    10. NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies

      NCI-MATCH precision medicine clinical trial releases new findings, strengthens path forward for targeted cancer therapies

      The NCI-MATCH precision medicine clinical trial has reached a milestone with the release of results from several study treatment arms. Findings from three arms were released at the 2018 ASCO annual meeting, adding to findings from one arm released in 2017.

      Read Full Article
    11. Anti-inflammatory strategy could lead to improved survival of children with neuroblastoma

      Anti-inflammatory strategy could lead to improved survival of children with neuroblastoma

      Download PDF Copy May 28, 2018 Researchers at Karolinska Institutet and Karolinska University Hospital have discovered that an anti-inflammatory drug candidate inhibiting the prostaglandin E2 producing enzyme mPGES-1 in the tumor stroma reduces tumor growth in experimental neuroblastoma models. The findings are published in EBioMedicine and open for new treatment strategies for this aggressive childhood cancer. "High-risk neuroblastoma is the most common and deadly cancer in infants.

      Read Full Article
      Mentions: Treatment
    12. Cancer Treatment and End-of-Life Care.

      Cancer Treatment and End-of-Life Care.

      J Palliat Med. 2018 May 16;:

      Authors: Sinha S, Matharu JK, Jacob J, Palat G, Brun E, Wiebe T, Segerlantz M

      Abstract AIM: To study to what extent tumor-specific treatment (chemo- or radiotherapy) was given during the last 30 days in life and to examine how many of the patients were referred to a specialized palliative care unit (PCU), at a low-resource governmental hospital in India.

      Read Full Article
    13. Emerging role of immunotherapy for childhood cancers.

      Emerging role of immunotherapy for childhood cancers.

      Chin Clin Oncol. 2018 Apr;7(2):14

      Authors: Handgretinger R, Schlegel P

      Abstract Recent developments in cell and gene therapy have a great impact on the new therapeutic approaches in pediatric cancers. Monoclonal antibodies for neuroblastoma and bispecific antibodies for leukemia have induced significant clinical responses for otherwise chemorefractory patients.

      Read Full Article
      Mentions: Immunotherapy
    14. Childhood Cancer Facts: By the Numbers

      Childhood Cancer Facts: By the Numbers

      Every year, an estimated 250,000+ new cases of cancer affect children under the age of 20 worldwide. Despite this, childhood cancer research is vastly and consistently underfunded. Check out the infographic below for more childhood cancer facts. You can also view and download the kid-friendly "Did You Know? Childhood Cancer Facts For Kids" infographic.

      Read Full Article
    15. Genetic analysis for certain childhood brain tumors soon a standard-of-care?

      Genetic analysis for certain childhood brain tumors soon a standard-of-care?

      An international team of researchers from the Hopp Children’s Cancer Center at the NCT Heidelberg (KiTZ), the European Molecular Biology Laboratory (EMBL) and the German Cancer Consortium (DKTK) together with colleagues at the St. Jude Children’s Research Hospital in Memphis and the Hospital for Sick Children in Toronto has summarized hereditary gene defects which can […]

      The post Genetic analysis for certain childhood brain tumors soon a standard-of-care? appeared first on Healthcanal.com.

      Read Full Article
    16. miRNA expression profile of bone marrow resident cells from children with neuroblastoma is not significantly different from that of healthy children.

      miRNA expression profile of bone marrow resident cells from children with neuroblastoma is not significantly different from that of healthy children.

      Oncotarget. 2018 Apr 10;9(27):19014-19025

      Authors: Stigliani S, Morandi F, Persico L, Lagazio C, Erminio G, Scaruffi P, Corrias MV

      Read Full Article
      Mentions: Bone Marrow
    17. Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of Neuroblastoma

      Targeted Doxorubicin-Loaded Bacterially Derived Nano-Cells for the Treatment of Neuroblastoma

      Advanced stage neuroblastoma is an aggressive disease with limited treatment options for patients with drug-resistant tumors. Targeted delivery of chemotherapy for pediatric cancers offers promise to improve treatment efficacy and reduce toxicity associated with systemic chemotherapy. The EnGeneIC Dream Vector (EDVTM) is a nanocell, which can package chemotherapeutic drugs and target tumors via attachment of bispecific proteins to the surface of the nanocell.

      Read Full Article
    18. [Clinical features and prognosis of malignancy-associated hemophagocytic lymphohistiocytosis in children: a clinical analysis of 24 cases].

      [Clinical features and prognosis of malignancy-associated hemophagocytic lymphohistiocytosis in children: a clinical analysis of 24 cases].

      Zhongguo Dang Dai Er Ke Za Zhi. 2018 Apr;20(4):295-297

      Authors: Zhang WY, Zhang Y, Dong NN, Wang YC, Sheng GY, Xu XJ, Liu YF

      Read Full Article
    1-24 of 211 1 2 3 4 5 6 7 8 9 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles

  3. Researches in the News

    1. (2 articles) Immunotherapy
    2. (1 articles) Nanoparticles
    3. (1 articles) MYCN
  4. Treatments in the News

    1. (2 articles) Surgery
    2. (1 articles) Side Effects